Amsterdam, Netherlands
Amsterdam, Netherlands

Time filter

Source Type

Patent
Stichting Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis and Agendia N.V. | Date: 2014-11-28

The invention relates to a method of assigning treatment to a breast and/or ovarian cancer patient. More specifically, the invention relates to a method for classification of breast and/or ovarian cancer as BRCA-like or sporadic-like by determining a level of expression of a set of genes and comparing said level of expression to a reference. A patient that is classified as BRCA-like is treated with a DNA-damage inducing agent.


IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that the American Medical Association (AMA) has granted a Category I, MAAA Current Procedural Terminology (CPT) Code for the MammaPrint 70-Gene Breast Cancer Recurrence Assay. “The approval of the Category 1 CPT code for MammaPrint is an important reimbursement milestone for Agendia,” commented Mark Straley, Chief Executive Officer, Agendia. “Foll


IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, highlights new data on its gold-standard MammaPrint 70-Gene Breast Cancer Recurrence Assay and BluePrint 80-Gene Molecular Subtyping Assay, from three studies presented at the San Antonio Breast Cancer Symposium last week. Researchers from the University of South Florida Morsani College of Medicine reported long-term follow-up data observing 148 patients who were tested with MammaPrint, Genomic Health’s Oncotype DX® and Clarient’s Mammastrat®. The study concluded that the different gene expression-based breast cancer recurrence tests showed discordant results, with only MammaPrint providing a definitive low or high risk outcome. MammaPrint also correctly reassigned a low or high risk result to intermediate Oncotype DX risk scores. The Agendia test was also the best predictor of distant cancer recurrence on identifying 85% of the 13 patients who either died or suffered a distant metastasis as high risk, compared to 54% for Oncotype DX and 62% for Mammostrat.1 The Multi Institutional Neo Adjuvant Therapy MammaPrint Project (MINT) trial demonstrated the predictive value of MammaPrint in further stratifying 183 patients classified as at high risk of their cancer recurring into High1 or High2 risk classes. Coupled with BluePrint, the study found that these MammaPrint high risk sub-groups together could help predict the benefit of chemotherapy.2 The third presentation, a sub-study of the international, prospective, phase III MINDACT trial, published in August 2016, compared molecular subtyping using BluePrint to pathological classification. Molecular subgroups within early-stage breast cancer (such as Luminal A, Luminal B, HER2+, Basel-like) may help to best identify patients for specific treatment approaches. A key conclusion was that molecular subtyping using BluePrint was able to restratify 16% of patients, originally classified pathologically high risk, to a low risk Luminal A-type group, with excellent survival. The study suggests that molecular subtyping by BluePrint is better correlated with outcome than pathological classification.3 The MINDACT trial, which was published in the New England Journal of Medicine, is a unique phase III prospective, randomized, controlled study that provides the highest level of clinical evidence to MammaPrint, above any other genomic assay, for making adjuvant chemotherapy decisions in early-stage breast cancer. It included almost 7,000 patients, across 112 institutions in nine different European countries. William Audeh, MD, Chief Medical Officer at Agendia said: “As the only gene expression-based breast cancer recurrence test supported by Level 1A clinical evidence, it is very good to see the value of MammaPrint, and also BluePrint demonstrated by these new data at this important symposium. The results highlight the benefit of these tests in providing patients with early stage breast cancer, and their physicians, with the confidence to make important, informed treatment decisions. It also demonstrates the potential to further apply our technology to truly individualize the prognosis and the prediction of the best breast cancer treatment, one patient at a time.” For more information on Agendia or the MammaPrint and BluePrint tests, you can visit Agendia’s patient site at KnowYourBreastCancer.com or the corporate site at Agendia.com. Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news. 1Russell S, et al. Long-term follow-up of early stage breast cancer patients with results of MammaPrint, Oncotype DX, and MammoStrat, risk classification assays. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas. 2Blumencranz L, et al. Mint trial yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subtype. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas. 3Cardoso F, et al. Can Surrogate Pathological Subtyping Replace Molecular Subtyping? Outcome Results from the MINDACT Trial. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas. MammaPrint is a FDA-cleared in vitro diagnostic test, available from FFPE sample, performed in a single laboratory, using the gene expression profile of breast cancer tissue samples to assess a patients' risk for distant metastasis. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. MammaPrint is not intended for diagnosis, or to predict or detect response to therapy, or to help select the optimal therapy for patients. Results should be taken in the context of other relevant clinical-pathological factors and standard practice of medicine. Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint FFPE 70-gene breast cancer recurrence assay as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods. In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. For more information, visit www.agendia.com.


Patent
Stichting Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis and Agendia N.V. | Date: 2013-10-10

The present invention relates to methods of typing a sample from an individual suffering from cancer. The invention further relates to methods for assigning treatment to an individual suffering from cancer, comprising typing a sample from an individual suffering from cancer according to the methods of the invention.


Patent
Stichting Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis and Agendia N.V. | Date: 2014-05-27

The invention relates to methods for determining the presence or absence of striatin-anaplastic lymphoma kinase (STRN-ALK) gene fusion and/or a Fibroblast Growth Factor Receptor 3transforming acidic coiled-coil containing protein 3 (FGFR3-TACC3) gene fusion in an individual, especially an individual suffering from lung cancer. The invention further relates to a method for diagnosing an individual as having adenocarcinoma, and to a method for treating said individual. The invention additionally relates to a method for diagnosing an individual as having squamous cell carcinoma, and to a method for treating said individual.


The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.


The invention provides a method for determining the percentage of tumor cells in a sample of an individual, preferably a breast sample. More specifically, the invention provides one or more genes than can be used to determine the percentage of tumor cells. The invention further provides a set of probes, a set of primers, and uses thereof for detection of said one or more genes.


The invention relates to a method of typing colorectal cancer cells by determining the RNA levels of a set of signature genes. Said typing can be use for predicting a risk for recurrence of said colorectal cancer. The invention further relates to a set of genes that can be used for normalizing the RNA levels of said set of signature genes, and to micro-array comprising said set of signature genes.


The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth factor Receptor 2 (ERBB2; HER2). More specifically, the invention provides methods and means to classify breast cancer as ER positive, triple negative (ER^(), PR^() and HER2^()) and HER2+.


WiseGuyReports.Com Publish a New Market Research Report On – “Biomarker Market by Manufacturers,Types,Regions and Applications Research Report Forecast to 2021”. This report studies Biomarker in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  Roche  Merck  Merck  BD  Abbott  Genesys Biolabs(20/20GeneSystems)  Affymetrix  Agendia  ALMAC  Arrayit  Biocartic  BG Medicine  KEGG EXPRESSION Database  Thermo Fisher  BGI For more information or any query mail at [email protected] Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Biomarker in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Type I  Type II  Type III Split by application, this report focuses on consumption, market share and growth rate of Biomarker in each application, can be divided into  Application 1  Application 2  Application 3 Global Biomarker Market Research Report 2016  1 Biomarker Market Overview  1.1 Product Overview and Scope of Biomarker  1.2 Biomarker Segment by Type  1.2.1 Global Production Market Share of Biomarker by Type in 2015  1.2.2 Type I  1.2.3 Type II  1.2.4 Type III  1.3 Biomarker Segment by Application  1.3.1 Biomarker Consumption Market Share by Application in 2015  1.3.2 Application 1  1.3.3 Application 2  1.3.4 Application 3  1.4 Biomarker Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Biomarker (2011-2021) 2 Global Biomarker Market Competition by Manufacturers  2.1 Global Biomarker Production and Share by Manufacturers (2015 and 2016)  2.2 Global Biomarker Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global Biomarker Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers Biomarker Manufacturing Base Distribution, Sales Area and Product Type  2.5 Biomarker Market Competitive Situation and Trends  2.5.1 Biomarker Market Concentration Rate  2.5.2 Biomarker Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 7 Global Biomarker Manufacturers Profiles/Analysis  7.1 Roche  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 Biomarker Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 Roche Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 Merck  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 Biomarker Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Merck Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 Merck  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 Biomarker Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Merck Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 BD  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 Biomarker Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 BD Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 Abbott  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 Biomarker Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Abbott Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 Genesys Biolabs(20/20GeneSystems)  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 Biomarker Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Genesys Biolabs(20/20GeneSystems) Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 Affymetrix  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 Biomarker Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 Affymetrix Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 Agendia  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 Biomarker Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 Agendia Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 ALMAC  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 Biomarker Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II  7.9.3 ALMAC Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.9.4 Main Business/Business Overview  7.10 Arrayit  7.10.1 Company Basic Information, Manufacturing Base and Its Competitors  7.10.2 Biomarker Product Type, Application and Specification  7.10.2.1 Type I  7.10.2.2 Type II  7.10.3 Arrayit Biomarker Production, Revenue, Price and Gross Margin (2015 and 2016)  7.10.4 Main Business/Business Overview  7.11 Biocartic  7.12 BG Medicine  7.13 KEGG EXPRESSION Database  7.14 Thermo Fisher  7.15 BGI For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Loading Agendia BV collaborators
Loading Agendia BV collaborators